Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,712 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structure-based design of PDK1 inhibitors.
Poulsen A, Blanchard S, Soh CK, Lee C, Williams M, Wang H, Dymock B. Poulsen A, et al. Among authors: williams m. Bioorg Med Chem Lett. 2012 Jan 1;22(1):305-7. doi: 10.1016/j.bmcl.2011.11.006. Epub 2011 Nov 9. Bioorg Med Chem Lett. 2012. PMID: 22119465
2-anilino-4-aryl-8H-purine derivatives as inhibitors of PDK1.
Blanchard S, Soh CK, Lee CP, Poulsen A, Bonday Z, Goh KL, Goh KC, Goh MK, Pasha MK, Wang H, Williams M, Wood JM, Ethirajulu K, Dymock BW. Blanchard S, et al. Among authors: williams m. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2880-4. doi: 10.1016/j.bmcl.2012.02.058. Epub 2012 Feb 27. Bioorg Med Chem Lett. 2012. PMID: 22437109
Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
Poulsen A, William A, Blanchard S, Nagaraj H, Williams M, Wang H, Lee A, Sun E, Teo EL, Tan E, Goh KC, Dymock B. Poulsen A, et al. Among authors: williams m. J Mol Model. 2013 Jan;19(1):119-30. doi: 10.1007/s00894-012-1528-7. Epub 2012 Jul 22. J Mol Model. 2013. PMID: 22820730
VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
Hart S, Novotny-Diermayr V, Goh KC, Williams M, Tan YC, Ong LC, Cheong A, Ng BK, Amalini C, Madan B, Nagaraj H, Jayaraman R, Pasha KM, Ethirajulu K, Chng WJ, Mustafa N, Goh BC, Benes C, McDermott U, Garnett M, Dymock B, Wood JM. Hart S, et al. Among authors: williams m. Mol Cancer Ther. 2013 Feb;12(2):151-61. doi: 10.1158/1535-7163.MCT-12-0466. Epub 2012 Dec 27. Mol Cancer Ther. 2013. PMID: 23270925 Free PMC article.
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
William AD, Lee AC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Tan E, Chen D, Williams M, Sun ET, Goh KC, Ong WC, Goh SK, Hart S, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW. William AD, et al. Among authors: williams m. J Med Chem. 2011 Jul 14;54(13):4638-58. doi: 10.1021/jm200326p. Epub 2011 Jun 15. J Med Chem. 2011. PMID: 21604762
Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer.
William AD, Lee AC, Goh KC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Lee CP, Wang H, Williams M, Sun ET, Hu C, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW. William AD, et al. Among authors: williams m. J Med Chem. 2012 Jan 12;55(1):169-96. doi: 10.1021/jm201112g. Epub 2011 Dec 29. J Med Chem. 2012. PMID: 22148278
Newborn with Atypical Progressive Hydrocephalus.
Williams M, Mazuru-Witten D, Florio K, Vachharajani A. Williams M, et al. Neoreviews. 2024 Jun 1;25(6):e380-e384. doi: 10.1542/neo.25-6-e380. Neoreviews. 2024. PMID: 38821911 No abstract available.
12,712 results
You have reached the last available page of results. Please see the User Guide for more information.